The stock has a 36-month beta value of 1.34. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NUVL is 44.49M, and at present, short sellers hold a 12.64% of that float. On June 19, 2025, the average trading volume of NUVL was 563.31K shares.
NUVL) stock’s latest price update
The stock of Nuvalent Inc (NASDAQ: NUVL) has decreased by -0.70 when compared to last closing price of 76.06. Despite this, the company has experienced a -1.79% fall in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-18 that CAMBRIDGE, Mass., June 18, 2025 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Christy Oliger to its Board of Directors.
NUVL’s Market Performance
Nuvalent Inc (NUVL) has seen a -1.79% fall in stock performance for the week, with a 3.03% gain in the past month and a -2.63% plunge in the past quarter. The volatility ratio for the week is 1.23%, and the volatility levels for the past 30 days are at 2.27% for NUVL. The simple moving average for the last 20 days is -0.50% for NUVL stock, with a simple moving average of -9.30% for the last 200 days.
Analysts’ Opinion of NUVL
Many brokerage firms have already submitted their reports for NUVL stocks, with UBS repeating the rating for NUVL by listing it as a “Buy.” The predicted price for NUVL in the upcoming period, according to UBS is $100 based on the research report published on March 14, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NUVL reach a price target of $110. The rating they have provided for NUVL stocks is “Buy” according to the report published on December 30th, 2024.
UBS gave a rating of “Neutral” to NUVL, setting the target price at $100 in the report published on October 24th of the previous year.
NUVL Trading at 3.26% from the 50-Day Moving Average
After a stumble in the market that brought NUVL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.46% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NUVL starting from Porter James Richard, who sale 27,000 shares at the price of $76.93 back on Jun 16 ’25. After this action, Porter James Richard now owns 249,062 shares of Nuvalent Inc, valued at $2,077,093 using the latest closing price.
Pelish Henry E., the Chief Scientific Officer of Nuvalent Inc, sale 200 shares at $79.82 during a trade that took place back on Jun 06 ’25, which means that Pelish Henry E. is holding 63,101 shares at $15,964 based on the most recent closing price.
Stock Fundamentals for NUVL
The total capital return value is set at -0.31. Equity return is now at value -35.69, with -33.17 for asset returns.
Currently, EBITDA for the company is -280.37 million with net debt to EBITDA at 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.48.
Conclusion
To sum up, Nuvalent Inc (NUVL) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
